51 results about "Thrombolytic treatment" patented technology

The present invention relates to methods for the diagnosis and evaluation of stroke and stroke sub-type. A variety of bio-markers are disclosed for assembling a panel for such diagnosis and evaluation. Methods are disclosed for selecting markers and correlating their combined levels with a clinical outcome of interest. In various aspects: the invention provides methods for early detection and differentiation of stroke subtypes, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for hemorrhagic transformation after thrombolyic therapy. Methods are disclosed that provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

The invention concerns the use of a mast cell activation- or degranulation-blocking agent in the manufacture of a medicament for preventing and treating cerebral complications caused by thrombolytic treatment. The invention also relates to treatment of patients suffering from cerebral complications associated with thrombolysis. Further, the invention provides thrombolytic compositions comprising a mast cell degranulation-blocking and/or mast cell activation-blocking agent present in a therapeutically effective amount to prevent or reduce any cerebral complications caused by the active thrombolytic component.

The invention provides compositions and methods for treating or imaging stenosis, stenotic lesions, occluded lumens, embolic phenomena or thrombotic disorders. The invention further provides compositions and methods for treating internal hemorrhage.

The present invention relates to the use of matrix metalloproteinase MMP-10 in the preparation of a pharmaceutical composition useful for thrombolytic therapy, it also being possible for said composition to contain a plasminogen activator. Additionally, the present invention relates to said pharmaceutical composition for the treatment of thrombotic disorders.

In the field of biological medicines, a use of prourokinase (proUK) and variants thereof in facilitated percutaneous coronary intervention (PCI) in patients with acute myocardial infarction is provided. The use includes: within 6 hrs after a patient is afflicted with accurate myocardial infarction (AMI), firstly, performing thrombolytic therapy with proUK or variants thereof, and then, performing a PCI operation, to dredge the infarction related artery (IRA) as soon as possible, and re-establish an effective forward blood flow, such that an ischemic myocardium is reperfused. According to the present invention, the facilitated PCI for treatment of AMI with the proUK or variants thereof has an effect superior to that of direct PCI.

The present invention relates to the use of G-CSF and derivatives thereof for extending the therapeutic window of subsequent thrombolytic treatment of acute stroke, and thereby, allowing the diagnostic examinations which are necessary prior to the thrombolytic treatment in order to avoid hemorrhagic and other severe adverse side effects of the thrombolysis.

Described herein are methods for the treatment of a human subject who has had a stroke by administering to the subject a pharmaceutical composition including an antagonist of the P2X4 receptor. The antagonist of the P2X4 receptor can be administered in the acute phase of stroke, optionally in combination with a thrombolytic therapeutic or a procedure on the subject involving a clot-removal device.

A method for treating a stroke patient with thrombolysis, wherein prior to treatment the patient is diagnosed in particular for exhibiting cerebral tissue at risk, a cerebral artery occlusion, and/or an absolute “mismatch volume”.

The invention relates to the field of medical devices, in particular to a thrombus prevention and treatment catheter which comprises an indwelling catheter. The indwelling catheter comprises an inner catheter and an outer catheter; the outer catheter sleeves the inner catheter; spaces between the inner catheter and the outer catheter are filled with anticoagulants, and the anticoagulants can be outwardly permeated via the outer catheter. The thrombus prevention and treatment catheter has the advantages that hollow gaps are reserved between the inner catheter and the outer catheter of the indwelling catheter and are filled with the anticoagulants, the anticoagulants can be slowly released into the blood of patients via the outer catheter at certain speeds when the thrombus prevention and treatment catheter is used, and accordingly the purposes of preventing and treating thrombus can be achieved; the concentration of the filled anticoagulants can be regulated if the patients already suffer from the thrombus, or the release speeds of the anticoagulants can be regulated, so that the purpose of thrombolytic therapy can be achieved.

The invention discloses an ultrasonic thrombus removal accessory of an implantable medical device. The ultrasonic thrombus removal accessory of the implantable medical device comprises an ultrasonic transducer and an ultrasonic signal generation assembly, the ultrasonic transducer comprises a first ultrasonic transduction piece and a second ultrasonic transduction piece, and the first ultrasonic transduction piece and the second ultrasonic transduction piece are buckled together to form a mounting cavity, so that at least part of the implanted medical device is located in the mounting cavity, and the ultrasonic signal generation assembly is connected with the first ultrasonic transduction piece and the second ultrasonic transduction piece. The ultrasonic thrombus removal accessory of the implantable medical device can be installed on the outer surfaces of implantable devices such as an artificial heart and an artificial blood vessel in advance, thrombolysis treatment is conducted immediately when thrombus grows on the implantable devices, use is convenient, and the treatment effect is good.

The present invention provides fusion proteins for targeted delivery of plasminogen activators to platelet-VWF complexes, or alternatively to the site where these are located, in a fibrin-independent manner. The fusion protein of the invention are for use in methods for the prevention or treatment of diseases or conditions associated with such platelet-VWF complexes, which may cause microvascular thrombosis in diseases such as e.g. thrombotic thrombocytopenic purpura. Preferred targeting agents for incorporation into the fusion proteins are e.g. nanobodies against VWF or platelets. Preferred plasminogen activators for use in the fusion proteins comprise the protease domains of uPA or tPA. The invention further pertains to nucleic acid molecule encoding the fusion proteins of the invention, e.g. a gene therapy vector, and to pharmaceutical compositions comprising the fusion proteins of the invention or such gene therapy vectors.

The invention provides a push sleeve applicable to an intravenous thrombolysis catheter. The push sleeve comprises a push sleeve tube body. The length of the push sleeve tube body is smaller than that of the intravenous thrombolysis catheter. The top end of the push sleeve tube body is provided with a marker line. The intravenous thrombolysis catheter is sleeved with the push sleeve tube body. After the intravenous thrombolysis catheter is implanted behind a blood clot, the push sleeve tube body is pushed, the length of a dosing part of the thrombolysis catheter is adjusted according to the marker line on the push sleeve tube body so that the length of the dosing part is identical to that of the blood clot, thrombolytic drug can be released more accurately and effectively, and the thrombolysis efficiency is improved; meanwhile, for a patient which accepts thrombolytic therapy once more, a thrombolysis catheter of a new specification does not need to be implanted again, and a doctor just needs to push the push sleeve tube body and determine a reasonable dosing interval; as a result, medical cost is lowered, the working intensity of medical workers is reduced, the problem of multiple specifications of the hrombolysis catheters is solved, and the push sleeve is reasonable, effective and convenient to operate.

The invention discloses a deep venous thrombolysis curative effect prediction method and system, a storage medium and a terminal. The method comprises the following steps: acquiring an MRI image of alower limb deep venous thrombosis patient; training the MRI image based on a semantic segmentation network to obtain a deep learning semantic segmentation model; extracting high-dimensional semantic features of lower limb deep vein thrombosis by adopting the deep learning semantic segmentation model, and performing feature screening on the high-dimensional semantic features by adopting a clustering algorithm; and performing lower limb deep venous thrombolysis curative effect prediction by adopting a thrombolysis curative effect prediction algorithm according to the screened semantic features to obtain a lower limb deep venous thrombolysis curative effect prediction result, and outputting the result. Based on the deep learning semantic segmentation network and the magnetic resonance image,the relation model between the semantic features and the thrombolysis curative effect of the thrombus is established, the thrombolysis curative effect of the thrombus of the patient is effectively predicted, the burden of doctors is relieved, and the diagnosis efficiency is improved.

The present invention discloses use of ginsenoside Rb₂ in the manufacture of drugs. Said drugs not only can dissolve thrombi and protect against reperfusion injury, but also can improve microcirculation, help to repair the injured tissues and cells, improve local or even systemic physiological conditions. Additional advantages include reduced bleeding time when used in thrombolytic treatment. Said drugs may be used in a wide range of diseases related to microcirculatory disorders, such as chronic coronary heart disease, vasculitis, thromboembolic diseases, Raynaud's disease, microvascular diseases of fundus oculi and the like. According to the present invention, said drugs may be formulated into injections, tablets, granules or capsules. According to a basic embodiment of the present invention, the purity of ginsenoside monomer Rb₂ may be around 80% and the rest components are essentially ginsenosides Rb₁ and Rb₃ in an amount of about 10%; the ginsenoside monomer Rb₂ may also be in a purity of 90% or more.

The invention discloses an intelligent device with a laser thrombus crushing function, which comprises a tube sheath, a guide wire and a catheter, the guide wire and the catheter are sleeved at the front end of the tube sheath, the tube sheath is arranged in a tube sheath fixer, and a holmium laser instrument for emitting holmium laser and a vacuum tube device for vacuum extraction of thrombus are arranged outside the tube sheath fixer. An optical fiber and a delivery tube which are respectively connected with the holmium laser instrument and the vacuum tube device are arranged in the catheter sheath fixer, the optical fiber and the delivery tube extend in the catheter in the same direction and extend out, and a laser head used for smashing thrombus by laser is arranged at the extending end of the optical fiber. The intelligent device with the thrombus laser smashing function can conduct vacuum extraction after large thrombus is smashed through laser, the problem that a patient is not suitable for thrombolysis treatment is solved, the intelligent device is high in precision, small, exquisite, flexible and free of limitation, deliverability of a support is guaranteed, and the success rate of an operation is increased.

The invention belongs to the field of medicines, and particularly relates to application of icaritin in preparation of a medicine for preventing and treating cerebral infarction hemorrhage transformation. The icaritin can significantly reduce primary hemorrhage transformation, asymptomatic hemorrhage transformation and secondary hemorrhage transformation risks caused by the use of thrombolytic drugs, anticoagulant drugs or antiplatelet drugs of cerebral infarction patients, significantly shorten the hemorrhage time and reduce the hemorrhage amount, does not change four coagulation tests and blood routine values when exerting the effects, does not affect the thrombolytic effect of the thrombolytic drugs, has a significant prevention effect for the hemorrhagic infarction which can be determined according to the first cranial CT/MRI, and has important significance for the improvement of the short-term and long-term curative effect of the thrombolytic treatment of infarction diseases.

The invention discloses fresh shaddock pulp aqueous extract powder, a preparation method of the fresh shaddock pulp aqueous extract powder and an application of the fresh shaddock pulp aqueous extractpowder in thrombolysis medicines and medicines still effective for treating ischemic stroke which breaks out for 24 hours. The fresh shaddock pulp aqueous extract powder prepared by the method provided by the invention contains 15 quinic acid compounds and 10 flavonoid compounds. Experiments prove that the fresh shaddock pulp aqueous extract powder not only has a good thrombolysis effect, but also has an exact curative effect on mice suffering from the ischemic stroke which breaks out for 24 hours, so that a technical means is provided for thrombolysis treatment, especially for effective treatment of the ischemic stroke which breaks out for 24 hours.

This invention provides an apparatus and method for emergency administration or self-administration of thrombolytic therapy in early stage of a heart attack. The apparatus includes a needle injector for making a venipuncture, a battery operated micro cooler for maintaining low temperature environment for vials with lyophilized thrombolytic and adjuvant drugs, a container with a diluent for reconstitution of the lyophilized drugs, a programmable infusion pump, and a microprocessor for controlling the process of infusion and recording the data. As the system is activated, said container becomes fluidly communicable with the infusion pump and vials with drugs in the cooler. Designed for autonomous execution of several schedules of infusion, it also can be controlled remotely by a qualified operator via an Internet interface.